One Charles Private Wealth Services LLC Cuts Stock Holdings in Pfizer Inc. (NYSE:PFE)

by · The Markets Daily

One Charles Private Wealth Services LLC lessened its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 8.2% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 9,513 shares of the biopharmaceutical company’s stock after selling 853 shares during the period. One Charles Private Wealth Services LLC’s holdings in Pfizer were worth $316,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of PFE. RB Capital Management LLC increased its holdings in Pfizer by 6.7% during the first quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock valued at $282,000 after buying an additional 341 shares during the period. Ironwood Wealth Management LLC. increased its holdings in shares of Pfizer by 1.1% in the 1st quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock valued at $1,868,000 after acquiring an additional 400 shares during the period. United Bank raised its position in shares of Pfizer by 0.6% in the 1st quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock worth $2,416,000 after acquiring an additional 290 shares in the last quarter. Ergoteles LLC lifted its stake in shares of Pfizer by 136.3% during the 1st quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock worth $1,903,000 after purchasing an additional 21,209 shares during the last quarter. Finally, Mackenzie Financial Corp boosted its position in Pfizer by 6.4% during the first quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock valued at $69,238,000 after purchasing an additional 79,887 shares in the last quarter. 68.05% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Performance

NYSE PFE opened at $27.76 on Friday. The firm has a market capitalization of $156.74 billion, a P/E ratio of 77.11, a PEG ratio of 1.24 and a beta of 0.62. The stock has a 50-day simple moving average of $28.07 and a two-hundred day simple moving average of $30.83. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.05 and a current ratio of 2.38. Pfizer Inc. has a fifty-two week low of $25.76 and a fifty-two week high of $42.22.

Pfizer (NYSE:PFE – Get Free Report) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.29. The company had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a return on equity of 10.61% and a net margin of 3.62%. Pfizer’s quarterly revenue was down 41.3% on a year-over-year basis. During the same period last year, the business earned $1.14 earnings per share. On average, equities analysts forecast that Pfizer Inc. will post 2.22 earnings per share for the current year.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 1st. Shareholders of record on Friday, January 26th will be given a $0.42 dividend. The ex-dividend date is Thursday, January 25th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.05%. This is an increase from Pfizer’s previous quarterly dividend of $0.41. Pfizer’s dividend payout ratio is 466.67%.

Analysts Set New Price Targets

PFE has been the subject of several analyst reports. Barclays decreased their price target on shares of Pfizer from $34.00 to $28.00 and set an “equal weight” rating for the company in a research report on Thursday, December 14th. Truist Financial lowered their target price on shares of Pfizer from $42.00 to $36.00 and set a “buy” rating for the company in a research note on Thursday, December 14th. Morgan Stanley reduced their price target on Pfizer from $39.00 to $37.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 1st. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Wednesday, January 31st. Finally, UBS Group reduced their target price on Pfizer from $34.00 to $27.00 and set a “neutral” rating on the stock in a research report on Thursday, December 14th. Eleven analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $36.88.

Check Out Our Latest Stock Report on PFE

Insider Transactions at Pfizer

In other Pfizer news, Director Scott Gottlieb purchased 3,000 shares of Pfizer stock in a transaction that occurred on Friday, December 15th. The stock was bought at an average price of $26.47 per share, with a total value of $79,410.00. Following the acquisition, the director now owns 9,000 shares of the company’s stock, valued at approximately $238,230. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.05% of the company’s stock.

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Recommended Stories

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).